234 related articles for article (PubMed ID: 36040492)
1. Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.
Mehta P; Balakrishnan A; Phatak S; Pathak M; Ahmed S
Rheumatol Int; 2023 Mar; 43(3):437-448. PubMed ID: 36040492
[TBL] [Abstract][Full Text] [Related]
2. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.
Segelmark M; Phillips BD; Hogan SL; Falk RJ; Jennette JC
Clin Diagn Lab Immunol; 2003 Sep; 10(5):769-74. PubMed ID: 12965902
[TBL] [Abstract][Full Text] [Related]
3. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis.
Guchelaar NAD; Waling MM; Adhin AA; van Daele PLA; Schreurs MWJ; Rombach SM
Autoimmun Rev; 2021 Jan; 20(1):102716. PubMed ID: 33197574
[TBL] [Abstract][Full Text] [Related]
4. Verification, implementation and harmonization of automated chemiluminescent immunoassays for MPO- and PR3-ANCA detection.
Ogrič M; Švec T; Poljšak KM; Žigon P; Hočevar A; Čučnik S
Clin Chem Lab Med; 2024 Mar; 62(4):682-689. PubMed ID: 37870064
[TBL] [Abstract][Full Text] [Related]
5. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
[TBL] [Abstract][Full Text] [Related]
6. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis.
Damoiseaux J; Dähnrich C; Rosemann A; Probst C; Komorowski L; Stegeman CA; Egerer K; Hiepe F; van Paassen P; Stöcker W; Schlumberger W; Tervaert JW
Ann Rheum Dis; 2009 Feb; 68(2):228-33. PubMed ID: 18375539
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Bornstein G; Ben-Zvi I; Furie N; Grossman C
Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis.
Damoiseaux JG; Slot MC; Vaessen M; Stegeman CA; Van Paassen P; Tervaert JW
J Clin Immunol; 2005 May; 25(3):202-8. PubMed ID: 15981084
[TBL] [Abstract][Full Text] [Related]
9. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays.
Damoiseaux J; Csernok E; Rasmussen N; Moosig F; van Paassen P; Baslund B; Vermeersch P; Blockmans D; Cohen Tervaert JW; Bossuyt X
Ann Rheum Dis; 2017 Apr; 76(4):647-653. PubMed ID: 27481830
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.
Hagen EC; Daha MR; Hermans J; Andrassy K; Csernok E; Gaskin G; Lesavre P; Lüdemann J; Rasmussen N; Sinico RA; Wiik A; van der Woude FJ
Kidney Int; 1998 Mar; 53(3):743-53. PubMed ID: 9507222
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
Front Immunol; 2020; 11():2053. PubMed ID: 33013868
[No Abstract] [Full Text] [Related]
12. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
Holding S; Fisher VJ; Abuzakouk M
Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
14. Testing and reporting antineutrophil cytoplasmic antibodies (ANCA) in treated vasculitis and non-vasculitic disease.
Savige J; Trevisin M; Pollock W
J Immunol Methods; 2018 Jul; 458():1-7. PubMed ID: 29486145
[TBL] [Abstract][Full Text] [Related]
15. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
[TBL] [Abstract][Full Text] [Related]
17. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.
Boomsma MM; Stegeman CA; van der Leij MJ; Oost W; Hermans J; Kallenberg CG; Limburg PC; Tervaert JW
Arthritis Rheum; 2000 Sep; 43(9):2025-33. PubMed ID: 11014352
[TBL] [Abstract][Full Text] [Related]
18. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
19. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis.
Aljuhani M; Makati D; Hoff A; Thompson J; Pellegrino B; Shawwa K; Schmidt R; Kannabhiran D
Rheumatol Int; 2021 May; 41(5):965-972. PubMed ID: 33585954
[TBL] [Abstract][Full Text] [Related]
20. A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies.
Bossuyt X; Rasmussen N; van Paassen P; Hellmich B; Baslund B; Vermeersch P; Blockmans D; Cohen Tervaert JW; Csernok E; Damoiseaux J
Rheumatology (Oxford); 2017 Sep; 56(9):1533-1541. PubMed ID: 28541581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
